Skip to content

Baseline and First Trimester Uterine Artery Doppler Velocimetry to Predict Poor Obstetric Outcomes in IVF

The Effect of Baseline and First Trimester Uterine Artery Doppler Velocimetry Parameters on Obstetric Outcomes in HRT-FET Cycles: Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05661539
Enrollment
500
Registered
2022-12-22
Start date
2022-06-01
Completion date
2024-04-15
Last updated
2023-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Female

Keywords

Uterine Artery Doppler Velocimetry, Baseline Uterine Artery Doppler Velocimetry, First Trimester Uterine Artery Doppler Velocimetry

Brief summary

The researchers aim to determine how baseline (preconceptional) and first-trimester uterine artery Doppler measurements affect obstetric complications in women undergoing high-quality blastocyst transfer and to determine the correlation between the two Doppler measurements.

Detailed description

Only patients with high-quality blastocyst-stage embryos will be included in the study. In frozen embryo transfer cycles prepared hormonally, basal bilateral uterine artery Doppler velocimetry will be performed before treatment (preconception) in each patient. Bilateral uterine artery Doppler velocimetry will be performed during the basal ultrasonography (2-5 days of menstruation). The absence of any uterine artery notches, diastolic or reverse flow will also be noted. In addition, sub-endometrial (arcuate artery) blood flows will be evaluated by Doppler ultrasonography. For endometrial preparation, estrogen replacement will be given for approximately 12-14 days as a routine In cases with endometrial thickness ≥7mm, progesterone treatment will be started and embryo transfer will be planned on the 6th day of the treatment. In the pregnant group, measurements will be repeated at the end of the first trimester (11-14 weeks) and uterine artery Doppler velocimetry will be reevaluated. In addition, patients will be followed up until delivery and possible obstetric complications will be recorded. Baseline and first-trimester uterine artery Doppler ultrasonography findings will be compared with obstetric results. Obstetric outcomes such as birth weight at the end of pregnancy, small-large for gestational age, presence of hypertension, and preterm delivery will be correlated with preconceptional and first-trimester uterine artery Doppler parameters.

Interventions

The amount of resistance and blood flow in the main arteries that provide uterine perfusion will be determined by uterine artery Doppler velocimetry performed on the patients.

Sponsors

Akdeniz University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years

Inclusion criteria

* Exogenous hormone preparation of the endometrial lining * High embryo quality ((≥2BB) according to Alpha criteria * Embryo transfer at the blastocyst stage

Exclusion criteria

* Patients whose treatments were canceled for any reason before the embryo transfer procedure * Patients who underwent embryo transfer in the cleavage stage * Presence of low-quality (\<2BB) blastocysts * \>15% loss of viability of the embryo during embryo thawing, * Patients with congenital uterine malformations, * Patients in whom Doppler velocimetry cannot be performed optimally

Design outcomes

Primary

MeasureTime frameDescription
Live Birth Rate9 monthspregnancy beyond 24 weeks of gestational age.
Obstetric Complication Rates20 weeks after embryo transferConditions such as preeclampsia, eclampsia, fetal growth restriction, oligohydramnios, polyhydramnios, preterm birth, gestational diabetes mellitus, antenatal bleeding and etc. that develop during pregnancy

Countries

Turkey (Türkiye)

Contacts

Primary ContactŞAFAK OLGAN, MD
safakolgan@gmail.com00905064068740
Backup ContactARİF C ÖZSİPAHİ, MD
a.canozsipahi@hotmail.com005068301073

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026